Baragi V M
Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, MI 48105, USA.
Curr Opin Investig Drugs. 2000 Oct;1(2):194-8.
The University of Pittsburgh is developing MFG-IRAP gene therapy for the potential treatment of arthritis. Phase II studies have commenced, including one trial in arthritis patients [225365]. A retrovirus (MFG-IRAP) is used in the ex vivo transfer of a cDNA encoding the human interleukin-1 receptor antagonist (IL-1Ra). The therapy is being tested in post-menopausal women, and involves the removal of some of their synovium, which is then transfected with the IRAP gene and reimplanted into the joint [188197]. A phase I rheumatoid arthritis trial of a therapy using the IL-1 antagonist gene therapy in synergy with soluble TNF alpha receptors was reported in March 1999 and was considered to be effective in producing an anti-arthritic effect [318398].
匹兹堡大学正在研发用于潜在治疗关节炎的MFG - IRAP基因疗法。二期研究已经开始，其中包括一项针对关节炎患者的试验[225365]。一种逆转录病毒（MFG - IRAP）用于体外转移编码人白细胞介素 - 1受体拮抗剂（IL - 1Ra）的cDNA。该疗法正在绝经后女性中进行测试，包括切除她们的部分滑膜，然后用IRAP基因进行转染并重新植入关节[188197]。1999年3月报道了一项使用IL - 1拮抗剂基因疗法与可溶性TNFα受体协同作用治疗类风湿性关节炎的一期试验，该试验被认为在产生抗关节炎效果方面是有效的[318398]。
